Want to see MBRX full AI Analyst Report?
MBRX Stock Chart & Stats
$0.61
$0.04(1.92%)
At close: 4:00 PM EDT
$0.61
$0.04(1.92%)
Day’s Range― - ―
52-Week Range$0.16 - $15.77
Previous CloseN/A
Volume44.49K
Average Volume (3M)1.80M
Market Cap
$14.90M
Enterprise Value$8.88
Total Cash (Recent Filing)$7.26M
Total Debt (Recent Filing)$292.00K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.13
Shares Outstanding19,477,380
10 Day Avg. Volume533,897
30 Day Avg. Volume1,798,994
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside1867.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Annamycin Clinical EfficacyThe preliminary remission results indicate meaningful anti-leukemic activity in a difficult relapsed or refractory AML population, including patients who failed venetoclax. If confirmed in later readouts, the data could support regulatory progress, partnering interest, and a stronger product pipeline.
Recent Financing Supports DevelopmentThe completed financing provides capital to continue the MIRACLE program and fund general operations over the near term. This reduces immediate execution pressure and allows management to pursue planned clinical milestones, although the funding does not eliminate longer-term financing needs.
Low Balance-sheet LeverageMinimal debt limits fixed repayment obligations and interest-related pressure while the company funds clinical development. This gives Moleculin greater flexibility than a similarly unprofitable biotech with substantial borrowing, even though equity capital remains important to sustain operations.
Bears Say
Pre-commercial With Persistent LossesMoleculin has not yet established commercial revenue to offset its research and development costs, leaving financial performance dependent on clinical progress rather than operating sales. Persistent losses limit internal funding capacity and make future value highly reliant on successful product development.
Continued Cash Burn Requires External FundingOngoing negative operating and free cash flow shows that the business cannot currently fund its activities from operations. Continued clinical spending will therefore require additional financing, partnering, or other capital sources, creating execution and funding dependence over the next several quarters.
Equity Erosion And Dilution RiskMaterial equity erosion reflects cumulative losses, while the recent share and warrant issuance can dilute existing holders as the company finances development. This may constrain per-share participation in future upside and signals that capital needs remain a significant structural shareholder risk.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $0.16 and its highest was $15.77 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $14.90M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 19, 2027 which is in 188 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Aug 14, 2026. The company reported -$1.4 earnings per share for the quarter, beating the consensus estimate of -$1.553 by $0.153.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 19,477,380 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$1.4 in its last earnings report, beating expectations of -$1.553. Following the earnings report the stock price went up 7.18%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
MBRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(1867.21% Upside)
Technical Analysis
Ownership Overview
5.44% Insiders
0.15% Mutual Funds
<0.01% Other Institutional Investors
94.19% Public Companies and
Individual Investors